WCG Expands Clinical Trial Technology and Services with Acquisition of VeraSci

Acquisition Adds Premier Expertise in CNS Disorders and Clinical Trial Endpoints and Assessments, Further Enriching WCG’s Leading CNS Scientific and Patient Engagement Capabilities PRINCETON, N.J., July 26, 2021 – WCG today announced the acquisition of VeraSci, a global provider of specialty scientific expertise and eClinical software to support the design and execution of clinical trials […]

CNS Trial Failure Rates High As Need for New Drugs Grows

The failure rate of CNS drugs in Phase 2 and 3 clinical trials is approximately 85%, second only to oncology. Because of the blood-brain barrier, the development of drugs for CNS indications presents particular challenges, as compounds need to be lipophilic in order to pass through that barrier. Over the past decade many larger pharmaceutical […]

On the Future of Movement Disorder Trials: Part 4 of WCG’s Transforming CNS Trials Series

      About this episode: Movement disorder trials have always been demanding. Now, sponsors face an additional challenge: How do you ensure data integrity in the era of remote clinical trials? In this podcast, Bob Dagher, M.D., WCG MedAvante-ProPhase’s Chief Medical Officer, addresses this in conversation with Steve Smith, WCG President of Patient Advocacy. […]

Viewing 1 - 10 of 56 articles